Immediate results of neoadjuvant chemotherapy for resectable colon cancer ; Непосредственные результаты неоадъювантной химиотерапии резектабельного рака ободочной кишки

Συγγραφείς: D. I. Azovsky, S. G. Afanasyev, L. V. Spirina, A. V. Avgustinovich, O. V. Cheremisina, S. V. Vtorushin, Д. И. Азовский, С. Г. Афанасьев, Л. В. Спирина, А. В. Августинович, О. В. Черемисина, С. В. Вторушин

Πηγή: Siberian journal of oncology; Том 24, № 1 (2025); 101-109 ; Сибирский онкологический журнал; Том 24, № 1 (2025); 101-109 ; 2312-3168 ; 1814-4861

Θεματικοί όροι: лекарственный патоморфоз, total neoadjuvant chemotherapy, combined treatment, immediate efficacy, toxicity, tumor regression, «тотальная» неоадъювантная химиотерапия, комбинированное лечение, непосредственная эффективность, токсичность

Περιγραφή αρχείου: application/pdf

Relation: https://www.siboncoj.ru/jour/article/view/3459/1318; Ferlay J., Ervik M., Lam F., Laversanne M., Colombet M., Mery L., Piñeros M., Znaor A., Soerjomataram I., Bray F. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer, 2024. [cited 2024 November 6]. URL: https://gco.iarc.who.int/today.; Состояние онкологической помощи населению России в 2023 году. Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М., 2024. 252 с.; Одинцова И.Н., Черемисина О.В., Писарева Л.Ф., Спивакова И.О., Вусик М.В. Эпидемиология колоректального рака в Томской области. Сибирский онкологический журнал. 2017; 16(4): 89–95. doi:10.21294/1814-4861-2017-16-4-89-95. EDN: ZFDGKP; Хазов А.В., Хрыков Г.Н., Эрдниев С.П., Савчук С.А. Неоадъювантное лечение местнораспространенного рака ободочной кишки (обзор литературы). Вопросы онкологии. 2019; 65(1): 63–68. EDN: ZDEXZJ.; Suenaga M., Fujimoto Y., Matsusaka S., Shinozaki E., Akiyoshi T., Nagayama S., Fukunaga Y., Oya M., Ueno M., Mizunuma N., Yamaguchi T. Perioperative FOLFOX4 plus bevacizumab for initially unresectable advanced colorectal cancer (NAVIGATE-CRC-01) Onco Targets Ther. 2015; 8: 1111–8. doi:10.2147/OTT.S83952.; Lerebours F., Rivera S., Mouret-Reynier M.A., Alran S., Venat-BouvetL., Kerbrat P., Salmon R., Becette V., BourgierC., CherelP., BoussionV., Balleyguier C., ThibaultF., Lavau-Denes S., NabholzJ.M., Sigal B., Trassard M., Mathieu M.C., Martin A.L., Lemonnier J., Mouret-Fourme E. Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Results of the UNICANCER CARMINA 02 French trial (UCBG 0609) Cancer. 2016; 122(19): 3032–40. doi:10.1002/cncr.30143.; Samalin E., Ychou M. Neoadjuvant therapy for gastroesophageal adenocarcinoma. World J Clin Oncol. 2016; 7(3): 284–92. doi:10.5306/wjco.v7.i3.284.; Yoshikawa T., Morita S., Tanabe K., Nishikawa K., Ito Y., Matsui T., Fujitani K., Kimura Y., Fujita J., Aoyama T., Hayashi T.,Cho H., Tsuburaya A., Miyashita Y., Sakamoto J. Survival results of a randomised two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of S-1 plus cisplatin (SC) and paclitaxel plus cisplatin (PC) followed by D2 gastrectomy for resectable advanced gastric cancer. Eur J Cancer. 2016; 62: 103–11. doi:10.1016/j.ejca.2016.04.012.; Grothey A., Sobrero A.F., Shields A.F., Yoshino T., Paul J., Taieb J., Souglakos J., Shi Q., Kerr R., Labianca R. Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med. 2018 Mar 29; 378(13): 1177–1188. doi:10.1056/NEJMoa1713709.; Ludmir E.B., Palta M., Willett C.G., Czito B.G. Total neoadjuvant therapy for rectal cancer:An emerging option. Cancer. 2017 May 1; 123(9): 1497–1506. doi:10.1002/cncr.30600.; Petrelli F., Trevisan F., Cabiddu M., Sgroi G., Bruschieri L., Rausa E., Ghidini M., Turati L. Total Neoadjuvant Therapy in Rectal Cancer: A Systematic Review and Meta-analysis of Treatment Outcomes.Ann Surg. 2020 Mar; 271(3): 440–448. doi:10.1097/SLA.0000000000003471.; Barrak D., Villano A.M., Moslim M.A., Hopkins S.E., Lefton M.D., Ruth K., Reddy S.S. Total Neoadjuvant Treatment for Pancreatic Ductal Adenocarcinoma IsAssociated With Limited Lymph Node Yield but Improved Ratio. J Surg Res. 2022; 280: 543–550. doi:10.1016/j.jss.2022.08.002.; Августинович А.В., Афанасьев С.Г., Добродеев А.Ю., Волков М.Ю., Костромицкий Д.Н., Спирина Л.В., Черемисина О.В. Непосредственная эффективность и токсичность тотальной неоадъювантной химиотерапии резектабельного рака желудка. Сибирский онкологический журнал. 2022; 21(1): 11–19. doi:10.21294/1814-4861-2022-21-1-11-19. EDN: AMBMXZ.; Liu S., Jiang T., Xiao L., Yang S., Liu Q., Gao Y., Chen G., Xiao W. Total Neoadjuvant Therapy (TNT) versus Standard Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: A Systematic Review and Meta-Analysis. Oncologist. 2021 Sep; 26(9): e1555-e1566. doi:10.1002/onco.13824.; Vogel J.D., Felder S.I., Bhama A.R., Hawkins A.T., Langenfeld S.J., Shaffer V.O., Thorsen A.J., Weiser M.R., Chang G.J., LightnerA.L., Feingold D.L., Paquette I.M. The American Society of Colon and Rectal Surgeons clinical practice guidelines for the management of colon cancer. Dis Colon Rectum 2022; 65(2): 148–177. doi:10.1097/DCR.0000000000002323.; Argilés G., Tabernero J., Labianca R., Hochhauser D., Salazar R., Iveson T., Laurent-Puig P., Quirke P., Yoshino T., Taieb J., Martinelli E., Arnold D.; ESMO Guidelines Committee. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020 Oct; 31(10): 1291–1305. doi:10.1016/j.annonc.2020.06.022.; Foxtrot Collaborative Group. Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial. Lancet Oncol. 2012; 13(11): 1152–60. doi:10.1016/S1470-2045(12)70348-0.; Jakobsen A., Andersen F., Fischer A., Jensen L.H., Jørgensen J.C.R., Larsen O., Lindebjerg J., Pløen J., Rafaelsen S.R., Vilandt J. Neoadjuvant chemotherapy in locally advanced colon cancer. A phase II trial. Acta Oncol. 2015; 54 (10):1747–53. doi:10.3109/0284186X.2015.1037007.; Arredondo J., Baixauli J., Pastor C., Chopitea A., Sola J.J., González I., A-Cienfuegos J., Martínez P., Rodriguez J., Hernández-Lizoain J.L. Mid-term oncologic outcome of a novel approach for locally advanced colon cancer with neoadjuvant chemotherapy and surgery. Clin Transl Oncol. 2017; 19(3): 379–385. doi:10.1007/s12094-016-1539-4.; Hu Z., Ding J., Ma Z., Sun R., Seoane J.A., Shaffer J.S., Suarez C.J., Berghoff A.S., Cremolini C., Falcone A., Loupakis F., Birner P., Preusser M., Lenz H.J., Curtis C. Quantitative evidence for early metastatic seeding in colorectal cancer. Nat Genet. 2019; 51(7): 1113–1122. doi:10.1038/s41588-019-0423-x.; Smith H.G., Chiranth D., Mortensen C.E., Schlesinger N.H. The significance of subdivisions of microscopically positive (R1) margins in colorectal cancer: a retrospective study of a national cancer registry. Colorectal Dis. 2022 Feb; 24(2): 197–209. doi:10.1111/codi.15971.; André T., Boni C., Mounedji-Boudiaf L., Navarro M., Tabernero J., Hickish T., Topham C., Zaninelli M., Clingan P., Bridgewater J., Tabah-Fisch I., de Gramont A. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004; 350 (23): 2343–51. doi:10.1056/NEJMoa032709.; Smith H.G., Skovgaards D.M., Bui N.H., Chiranth D., Qvortrup C., Schlesinger N.H. Differences in adjuvant chemotherapy and oncological outcomes according to margin status in patients with stage III colon cancer. Acta Oncol. 2023; 62(6): 594–600. doi:10.1080/0284186X.2023.2218555.; André T., Boni C., Navarro M., Tabernero J., Hickish T., Topham C., Bonetti A., Clingan P., Bridgewater J., Rivera F. de Gramont A. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009 Jul 1; 27(19): 3109–16. doi:10.1200/JCO.2008.20.6771.; Bayraktar U.D., Chen E., Bayraktar S., Sands L.R., Marchetti F., Montero A.J., Rocha-Lima C.M.S. Does delay of adjuvant chemotherapy impact survival in patients with resected stage II and III colon adenocarcinoma? Cancer. 2011; 117(11): 2364–70. doi:10.1002/cncr.25720.; https://www.siboncoj.ru/jour/article/view/3459

Διαθεσιμότητα: https://www.siboncoj.ru/jour/article/view/3459
https://doi.org/10.21294/1814-4861-2025-24-1-101-109

Three-year results of the Russian multicenter prospective randomized trial RuCort3 ; Трехлетние результаты российского многоцентрового проспективного рандомизированного исследования RuCort3

Συγγραφείς: A. V. Polynovsky, D. V. Kuzmichev, A. A. Tryakin, M. V. Chernykh, O. A. Kuznetsova, I. A. Karasev, D. V. Aleksantsev, A. M. Karachun, E. V. Tkachenko, E. I. Turyaeva, D. V. Samsonov, I. M. Gridasov, S. E. Prokofiev, Z. Z. Mamedli, А. В. Полыновский, Д. В. Кузьмичев, А. А. Трякин, М. В. Черных, О. А. Кузнецова, И. А. Карасев, Д. В. Алексанцев, А. М. Карачун, Е. В. Ткаченко, Е. И. Тюряева, Д. В. Самсонов, И. М. Гридасов, С. Е. Прокофьев, З. З. Мамедли

Πηγή: Surgery and Oncology; Том 15, № 1 (2025); 18-27 ; Хирургия и онкология; Том 15, № 1 (2025); 18-27 ; 2949-5857

Θεματικοί όροι: индукционная/консолидирующая химиотерапия, total neoadjuvant chemotherapy, chemoradiotherapy, induction/consolidation chemotherapy, тотальная неоадъювантная химиотерапия, химиолучевая терапия

Περιγραφή αρχείου: application/pdf

Relation: https://www.onco-surgery.info/jour/article/view/777/490; Злокачественные новообразования в России в 2018 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2019. 250 с.; Breugom A.J., van den Broek C.B.M., van Gijn W. et al. The value of adjuvant chemotherapy in rectal cancer patients after preoperative radiotherapy or chemotherapy followed by TMEsurgery: the PROCTOR/SCRIPT study. Eur J Cancer 2013;49:1.; Cionini L., Sainato A., de Paoli A. et al. Final results of randomized trial on adjuvant chemotherapy after preoperative chemoradiation in rectal cancer. Radiother Oncol 2010;96:113–4.; Glynne-Jones R., Chau I. Neoadjuvant therapy before surgical treatment. EJC Suppl 2013;11(2):45–59.; Rödel C., Liersch T., Becker H. et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/ AIO-04 randomised phase 3 trial. Lancet Oncol 2012;13:679–87.; Ludmir E.B., Palta M., Willett C.G. et al. Total neoadjuvant therapy for rectal cancer: an emerging option. Cancer 2017;123:1497–506. DOI:10.1002/cncr.30600; Franke A.J., Parekh H., Starr J.S. et al. Total neoadjuvant therapy: a shifting paradigm in locally advanced rectal cancer management. Clin Colorectal Cancer 2018;17:1–12.; Bahadoer R.R., Dijkstra E.A., van Etten B. et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol 2020;22(1):29–42. DOI:10.1016/S1470-2045(20)30555-6; Conroy T., Bosset J.-F., Etienne P-L. et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, openlabel, phase 3 trial. Lancet Oncol 2021;22(5):702–15. DOI:10.1016/S1470-2045(21)00079-6; Jin J., Tang Y., Hu C. et al. Multicenter, randomized, phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR). J Clin Oncol 2022;40(15):1681–92. DOI:10.1200/JCO.21.01667; Liao C.-K., Kuo Y.-T., Lin Y.-C. et. al. Neoadjuvant short-course radiotherapy followed by consolidation chemotherapy before surgery for treating locally advanced rectal cancer: a systematic review and meta-analysis. Curr Oncol 2022;29(5):3708–27. DOI:10.3390/curroncol29050297; Gabbani M., Giorgi C., Napoli G. et al. Outcomes of locally advanced rectal cancer patients treated with total neoadjuvant treatment: a meta-anaysis of randomized controlled trials. Clin Colorectal Cancer 2022;21(4):297–308. DOI:10.1016/j.clcc.2022.07.005; Petrelli F., Trevisan F., Cabiddu M. et al. Total neoadjuvant therapy in rectal cancer: a systematic review and meta-analysis of treatment outcomes. Ann Surg 2020;271(3):440–8. DOI:10.1097/SLA.0000000000003471; Liu S., Jiang T., Xiao L. et al. Total neoadjuvant therapy versus standard neoadjuvant chemoradiotherapy for locally advanced rectal cancer: a systematic review and meta-analysis. Oncologist 2021;26(9):e1555–e6. DOI:10.1002/onco.13824; Maas M., Nelemans P.J., Valentini V. et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol 2010;11:835–44.; Habr-Gama A., Perez R.O., Nadalin W. et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg 2004;240(4):711–7. DOI:10.1097/01.sla.0000141194.27992.32; Romesser P.B., Park B.K., Nemirovsky D. et al. Organ preservation and total neoadjuvant therapy for rectal cancer: investigating long course chemoradiation versus short-course radiation therapy. J Clin Oncol 2023;41(4):10. DOI:10.1200/JCO.2023.41.4_suppl.10; Cionini L., Sainato A., de Paoli A. et al. Final results of randomized trial on adjuvant chemotherapy after preoperative chemoradiation in rectal cancer. Radiother Oncol 2010;96:S113–4.

Διαθεσιμότητα: https://www.onco-surgery.info/jour/article/view/777
https://doi.org/10.17650/2949-5857-2025-15-1-18-27

Предварительные результаты многоцентрового российского рандомизированного исследования RUCORT3: лечение больных местнораспространенным раком прямой кишки (МРРПК)

Συγγραφείς: А. В. Полыновский, З. З. Мамедли, Д. В. Кузьмичев, А. А. Анискин, Д. В. Алексанцев

Πηγή: Malignant tumours; Том 12, № 3s1 (2022); 69-75 ; Злокачественные опухоли; Том 12, № 3s1 (2022); 69-75 ; 2587-6813 ; 2224-5057

Θεματικοί όροι: индукционная / консолидирующая химиотерапия, тотальная неоадъювантная химиотерапия, химиолучевая терапия

Περιγραφή αρχείου: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/1003/700; Kaprin A. D. Malignant neoplasms in Russia in 2018 (morbidity and mortality) // P. Hertsen Moscow Oncology Research Institute, 2019–249 p.; Breugom AJ, van den Broek CBM, van Gijn W, et al. The value of adjuvant chemotherapy in rectal cancer patients after preoperative radiotherapy or chemotherapy followed by TME-surgery : the PROCTOR / SCRIPT study // Eur J Cancer. 2013. 49, S1.; Cionini L, Sainato A, De Paoli A et al. Final results of randomized trial on adjuvant chemotherapy after preoperative chemoradiation in rectal cancer. // Radiother Oncol. 2010. 96, S113-S114.; Glynne-Jones R, Chau I. Neoadjuvant therapy before surgical treatment. // EJC Suppl. 2013 EJC Suppl. 2013. 11 (2), 45–59.; Rödel C, Liersch T, Becker H, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer : initial results of the German CAO / ARO / AIO-04 randomised phase 3 trial. Lancet Oncol. 2012; 13 : 679–687.].; Ludmir EB, Palta M, Willett CG, et al. Total neoadjuvant therapy for rectal cancer : An emerging option. Cancer. 2017; 123 : 1497–1506. doi:10.1002/cncr.30600.; Franke AJ, Parekh H, Starr JS, et al. Total neoadjuvant therapy : a shifting paradigm in locally advanced rectal cancer management. Clin Colorectal Cancer. 2018; 17 : 1–12.; Gabbani M., Giorgi C., Napoli G. et al. Outcomes of Locally Advanced Rectal Cancer Patients Treated with Total Neoadjuvant Treatment : A Meta-Anaysis of Randomized Controlled Trials. Clinical Colorectal Cancer, Vol. 000, No. xxx, 1–12 ©2022.; Fernández-Martos C., Pericay C., Aparicio J., et al. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defi ned, locally advanced rectal cancer : Grupo cancer de recto 3 study. J Clin Oncol. 2010; 28 (5) : 859–65.; Fokas E., Phil D., Allgauer M. et al. Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer : CAO / ARO / AIO-12. Journal of Clinical Oncology 2019; 37. DOI https://doi.org/10.1200/JCO.19.00308.; Gao Y. H., Lin J. Z., An X. et al. Neoadjuvant Sandwich Treatment with Oxaliplatin and Capecitabine Administered Prior to, Concurrently with, and Following Radiation Therapy in Locally Advanced Rectal Cancer : a Prospective Phase 2 Trial // Int. J. Radiat. Oncol. Biol. Phys. 2014. V. 90, No. 5. P. 1153–1160.; Marco MR, Zhou L, Patil S, et al : Consolidation mFOLFOX6 chemotherapy after chemoradiotherapy improves survival in patients with locally advanced rectal cancer : Final results of a multicenter phase II trial. Dis Colon Rectum 61 : 1146–1155, 2018.; Maas M, Nelemans PJ, Valentini V, et al : Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer : A pooled analysis of individual patient data. Lancet Oncol 11 : 835–844, 2010.; https://www.malignanttumors.org/jour/article/view/1003

Διαθεσιμότητα: https://www.malignanttumors.org/jour/article/view/1003
https://doi.org/10.18027/2224-5057-2022-12-3s1-69-75